Sitagliptin + Metformin Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50/500 mg, 50/850 mg, 50/1000 mg
Reference Brands: Janumet (US & EU)
Category:
Diabetes
Sitagliptin + Metformin combines DPP-4 inhibition with insulin sensitization. Sitagliptin boosts incretin hormones, enhancing insulin release and reducing glucagon. Metformin decreases hepatic glucose production and improves peripheral glucose uptake. This dual mechanism provides superior glycemic control, lowers HbA1c, and minimizes hypoglycemia risk—ideal for managing Type 2 diabetes effectively.
Sitagliptin + Metformin tablets is available in Tablets
and strengths such as 50/500 mg, 50/850 mg, 50/1000 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sitagliptin + Metformin tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sitagliptin + Metformin tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sitagliptin + Metformin tablets are FDA-approved in the USA and EMA-authorized in the EU for managing type 2 diabetes. These fixed-dose combination tablets comply with GMP standards and serve as adjuncts to diet and exercise. Marketed under brands like Janumet®, they require regulatory labeling for risks like lactic acidosis and renal impairment. Pharmacovigilance is mandatory in both regions. Manufacturers must adhere to 21 CFR (USA) and EMA Modules 1–5 (EU). For regulatory support, sourcing, or B2B pharma solutions, visit PharmaTradz.com — your global partner in compliant pharmaceutical trade.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing